These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 8347328)
1. A pilot clinical trial of the angiotensin-converting enzyme inhibitor ceranapril in Alzheimer disease. Sudilovsky A; Cutler NR; Sramek JJ; Wardle T; Veroff AE; Mickelson W; Markowitz J; Repetti S Alzheimer Dis Assoc Disord; 1993; 7(2):105-11. PubMed ID: 8347328 [TBL] [Abstract][Full Text] [Related]
2. Ceranapril (SQ 29,852), an orally active inhibitor of angiotensin converting enzyme (ACE). DeForrest JM; Waldron TL; Harvey C; Scalese R; Hammerstone S; Powell JR; Karanewsky D J Cardiovasc Pharmacol; 1990 Jul; 16(1):121-7. PubMed ID: 1696654 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects. Duchin KL; Waclawski AP; Tu JI; Manning J; Frantz M; Willard DA J Clin Pharmacol; 1991 Jan; 31(1):58-64. PubMed ID: 1646240 [TBL] [Abstract][Full Text] [Related]
4. Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease. Barnes NM; Cheng CH; Costall B; Naylor RJ; Williams TJ; Wischik CM Eur J Pharmacol; 1991 Aug; 200(2-3):289-92. PubMed ID: 1664329 [TBL] [Abstract][Full Text] [Related]
5. Characterisation of [3H]ceranapril recognition sites in rat and human brain tissue. Barnes NM; Costall B; Egli P; Horovitz ZP; Ironside JW; Naylor RJ; Williams TJ Neuropharmacology; 1991 Aug; 30(8):907-14. PubMed ID: 1664073 [TBL] [Abstract][Full Text] [Related]
6. Hypotensive effects and influence on serum lipids of SQ29,852, a new angiotensin converting enzyme inhibitor, in patients with essential hypertension: a comparison with atenolol. Sasaki J; Koga S; Kato K; Takii M; Sakai K; Kawasaki K; Kagimoto M; Doi Y; Takada K; Sakaue A Int J Clin Pharmacol Ther Toxicol; 1993 Feb; 31(2):83-8. PubMed ID: 8458681 [TBL] [Abstract][Full Text] [Related]
7. The use of the Computerized Neuropsychological Test Battery (CNTB) in an efficacy and safety trial of BMY 21,502 in Alzheimer's disease. Cutler NR; Shrotriya RC; Sramek JJ; Veroff AE; Seifert RD; Reich LA; Hironaka DY Ann N Y Acad Sci; 1993 Sep; 695():332-6. PubMed ID: 8239308 [TBL] [Abstract][Full Text] [Related]
8. Ceranapril and cerebral blood flow autoregulation. Torup M; Waldemar G; Paulson OB J Hypertens; 1993 Apr; 11(4):399-405. PubMed ID: 8390507 [TBL] [Abstract][Full Text] [Related]
9. Hypotensive effect of a phosphorus-containing novel angiotensin converting enzyme inhibitor, (S)-1-[6-amino-2[[hydroxy(4-phenylbutyl)phosphinyl] oxy]-1-oxohexyl]-L-proline (SQ 29,852) in conscious hypertensive dogs. Ohara N; Takizawa M; Yokota S; Ogawa N; Katsumura H; Ono H J Pharmacobiodyn; 1992 Jun; 15(6):267-76. PubMed ID: 1432566 [TBL] [Abstract][Full Text] [Related]
10. Effects of angiotensin II and an angiotensin converting enzyme inhibitor on alcohol intake in P and NP rats. Grupp LA Pharmacol Biochem Behav; 1992 Jan; 41(1):105-8. PubMed ID: 1539057 [TBL] [Abstract][Full Text] [Related]
11. A new assessment tool for neuropsychopharmacologic research: the Computerized Neuropsychological Test Battery. Veroff AE; Cutler NR; Sramek JJ; Prior PL; Mickelson W; Hartman JK J Geriatr Psychiatry Neurol; 1991; 4(4):211-7. PubMed ID: 1789909 [TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Coric V; van Dyck CH; Salloway S; Andreasen N; Brody M; Richter RW; Soininen H; Thein S; Shiovitz T; Pilcher G; Colby S; Rollin L; Dockens R; Pachai C; Portelius E; Andreasson U; Blennow K; Soares H; Albright C; Feldman HH; Berman RM Arch Neurol; 2012 Nov; 69(11):1430-40. PubMed ID: 22892585 [TBL] [Abstract][Full Text] [Related]
13. Effect of the ACE inhibitor ceronapril on cerebral blood flow in hypertensive patients. Cutler NR; Sramek JJ; Luna A; Mena I; Brass EP; Kurtz NM; Brennan JJ Ann Pharmacother; 1996 Jun; 30(6):578-82. PubMed ID: 8792940 [TBL] [Abstract][Full Text] [Related]
14. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. Schneider LS; Olin JT; Pawluczyk S Am J Psychiatry; 1993 Feb; 150(2):321-3. PubMed ID: 8422085 [TBL] [Abstract][Full Text] [Related]
15. Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. Cice G; Di Benedetto A; D'Isa S; D'Andrea A; Marcelli D; Gatti E; Calabrò R J Am Coll Cardiol; 2010 Nov; 56(21):1701-8. PubMed ID: 21070920 [TBL] [Abstract][Full Text] [Related]
16. (Phosphinyloxy)acyl amino acid inhibitors of angiotensin converting enzyme (ACE). 1. Discovery of (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L -proline a novel orally active inhibitor of ACE. Karanewsky DS; Badia MC; Cushman DW; DeForrest JM; Dejneka T; Loots MJ; Perri MG; Petrillo EW; Powell JR J Med Chem; 1988 Jan; 31(1):204-12. PubMed ID: 3336020 [TBL] [Abstract][Full Text] [Related]
17. Effect of naltrexone on senile dementia of the Alzheimer type. Hyman BT; Eslinger PJ; Damasio AR J Neurol Neurosurg Psychiatry; 1985 Nov; 48(11):1169-71. PubMed ID: 3001233 [TBL] [Abstract][Full Text] [Related]
18. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Asthana S; Craft S; Baker LD; Raskind MA; Birnbaum RS; Lofgreen CP; Veith RC; Plymate SR Psychoneuroendocrinology; 1999 Aug; 24(6):657-77. PubMed ID: 10399774 [TBL] [Abstract][Full Text] [Related]
19. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Anderson C; Teo K; Gao P; Arima H; Dans A; Unger T; Commerford P; Dyal L; Schumacher H; Pogue J; Paolasso E; Holwerda N; Chazova I; Binbrek A; Young J; Yusuf S; Lancet Neurol; 2011 Jan; 10(1):43-53. PubMed ID: 20980201 [TBL] [Abstract][Full Text] [Related]
20. A specific orally active inhibitor of angiotensin-converting enzyme in man. Ferguson RK; Turini GA; Brunner HR; Gavras H; McKinstry DN Lancet; 1977 Apr; 1(8015):775-8. PubMed ID: 66571 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]